纳武单抗在一名患有咽上缩肌癌并伴有溃疡性结肠炎病史患者中的安全应用：一例组织学确诊病例报告
Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report.
作者信息
Hijikata Yasuki, Matsubara Yasuo, Ota Yasunori, Lim Lay Ahyoung, Tani Kenzaburo, Hirata Yoshihiro, Yotsuyanagi Hiroshi
机构信息
Department of General Medicine, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Japan.
Department of Diagnostic Pathology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Japan.
出版信息
Intern Med. 2020 Apr 15;59(8):1105-1109. doi: 10.2169/internalmedicine.3901-19. Epub 2020 Feb 1.
Nivolumab, an antibody against human programmed cell death 1 (PD-1), enhances pre-existing immune responses and has antitumor activity. However, it may also cause undesirable immune-related adverse events (irAEs), such as anti-PD-1-related colitis. In addition, Nivolumab can worsen pre-existing autoimmune diseases. Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. Its exact cause is unknown, but it may involve the dysregulation of the mucosal immune response. Thus, it is of great interest whether nivolumab can affect UC activity. This is the first report of a patient with epipharyngeal carcinoma and ulcerative colitis who was confirmed to have been safely treated with nivolumab based on autopsy findings.
纳武单抗是一种针对人类程序性细胞死亡蛋白1（PD-1）的抗体，可增强已有的免疫反应并具有抗肿瘤活性。然而，它也可能引发不良的免疫相关不良事件（irAE），如抗PD-1相关的结肠炎。此外，纳武单抗会使已有的自身免疫性疾病恶化。溃疡性结肠炎（UC）是结肠的一种慢性炎症性疾病。其确切病因尚不清楚，但可能涉及黏膜免疫反应的失调。因此，纳武单抗是否会影响UC的病情活动备受关注。这是首例关于下咽癌合并溃疡性结肠炎患者的报告，基于尸检结果证实该患者接受纳武单抗治疗安全有效。
Zotero 插件